key: cord-0861957-3ez6vkxa authors: Cosma, S.; Carosso, A.; Cusato, J.; Borella, F.; Carosso, M.; Bovetti, M.; Filippini, C.; D'Avolio, A.; Ghisetti, V.; Di Perri, G.; Benedetto, C. title: COVID-19 and first trimester spontaneous abortion: a case-control study of 225 pregnant patients date: 2020-06-20 journal: nan DOI: 10.1101/2020.06.19.20135749 sha: 9d15b3381feaec474b7b9e4967b3f66b75520641 doc_id: 861957 cord_uid: 3ez6vkxa Background Evidence for the impact of COVID-19 during the second and the third trimester of pregnancy is limited to a relatively small series, while data on the first trimester are scant. With this study we evaluated COVID-19 infection as a risk factor for spontaneous abortion in first trimester of pregnancy. Methods Between February 22 and May 21, 2020, we conducted a case-control study at S. Anna hospital, Torino, among first trimester pregnant women, paired for last menstruation. The cumulative incidence of COVID-19 was compared between women with spontaneous abortion (case group, n=100) and those with ongoing pregnancy (control group, n=125). Current or past infection was determined by detection of SARS-CoV-2 from nasopharingeal swab and SARS-CoV-2 IgG/IgM antibodies in blood sample. Patient demographics, COVID-19-related symptoms, and the main risk factors for abortion were collected. Findings Twenty-three (10.2%) of the 225 women tested positive for COVID-19 infection. There was no difference in the cumulative incidence of COVID-19 between the cases (11/100, 11%) and the controls (12/125, 9.6%) (p=0.73). Logistic regression analysis confirmed that COVID-19 was not an independent predictor of abortion (1.28 confidence interval 0.53-3.08). Interpretation COVID-19 infection during the first trimester of pregnancy does not appear to predispose to abortion; its cumulative incidence did not differ from that of women with ongoing pregnancy. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 20, 2020. . https://doi.org/10.1101/2020.06.19.20135749 doi: medRxiv preprint 50 trimester pregnant women, paired for last menstruation. The cumulative incidence of COVID-19 was compared 51 between women with spontaneous abortion (case group, n=100) and those with ongoing pregnancy (control group, 52 n=125). Current or past infection was determined by detection of SARS-CoV-2 from nasopharingeal swab and SARS-53 CoV-2 IgG/IgM antibodies in blood sample. Patient demographics, COVID-19-related symptoms, and the main risk 54 factors for abortion were collected. Findings 57 Twenty-three (10.2%) of the 225 women tested positive for COVID-19 infection. There was no difference in the 58 cumulative incidence of COVID-19 between the cases (11/100, 11%) and the controls (12/125, 9.6%) (p=0.73). Logistic regression analysis confirmed that COVID-19 was not an independent predictor of abortion (1.28 confidence 60 interval 0.53-3.08). Interpretation 63 COVID-19 infection during the first trimester of pregnancy does not appear to predispose to abortion; its cumulative 64 incidence did not differ from that of women with ongoing pregnancy . 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The World Health Organization (WHO) named the new coronavirus (SARS-CoV-2) disease coronavirus disease-19 84 and declared it a pandemic. Coronaviruses are enveloped, non-segmented positive-sense RNA usually 85 responsible for mild illness such as the common cold in adults and children. 1 SARS, MERS) reported higher rates of preterm birth, preeclampsia, cesarean section, and perinatal death. 9 The lack of 93 data on abortion due to COVID-19 during the first trimester precludes extrapolation of conclusive evidence for the 94 effects of infection during early pregnancy. The paucity of reliable data has aroused concern in patients, while the 95 disinformation reported by media may lead pregnant women to embrace dramatic choices such as voluntary abortion. 10 The wide of clinical expression, the high rate of asymptomatic forms, the poor accuracy of nasopharyngeal swab testing 97 and its limited availability have been the main barriers to gaining a real understanding of the prevalence of the infection 98 and its impact on pregnancy. In this complex scenario, the development of serological tests for the detection of SARS-99 CoV-2 IgG and IgM could be useful to identify pregnant patients who were infected during early pregnancy. While the 100 quantity and quality of data on test performance are still limited, the level of accuracy has been reportedly 101 moderate/good, so that patients infected by SARS-CoV-2 can be traced. 11 The aim of the present study was to evaluate the impact of COVID-19 on first trimester spontaneous abortion by 103 comparing the cumulative incidence of SARS-CoV-2 infection in a cohort of women who experienced early abortion 104 and that of women with ongoing pregnancy at 12 weeks of gestational age. Women who had been referred to our Hospital for first trimester spontaneous abortion care between February 22 and 108 May 21, 2020 were contacted and enrolled (case group). Women 12 weeks pregnant admitted to our Hospital for fetal 109 nuchal translucency between April 16 and May 21, 2020 were the control group. The first reported case of COVID-19 110 infection in Piedmont was dated February 22, 2020. To exclude the possibility of COVID-19 seroconversion before 111 pregnancy, only women with last menstruation before that date were considered eligible for inclusion (Fig. 1 ). This 112 criterion allowed us to define seropositivity in the case group as a seroconversion that had occurred during pregnancy. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 20, 2020. Role of funding source The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the 143 report. The corresponding author had full access to all the data in the study and had final responsibility for the decision 144 to submit for publication. A total of 225 women at first trimester of pregnancy, attending our Institute were included in the study. One hundred 148 women in the case group and 125 women in the control group were enrolled. The patient adhesion rate was 87% 149 (100/115) and 88% (125/142), respectively. Table 1 presents the patients' characteristics at baseline; except for age, 150 there were no statistically significant differences in demographics or risk factors for abortion between the two groups. Twenty-three of the 225 women tested for anti-SARS-CoV-2 IgG and IgM antibodies were found to be seropositive or 152 their nasopharyngeal swab tested positive for COVID-19, yielding an overall cumulative incidence of 10.2% in the first 153 trimester. There was no significant difference in the cumulative incidence of COVID-19 between the case patients 154 (11/100, 11%) and the controls (12/125, 9.6%) (p=0.73). The age variable was entered into logistic regression analysis to evaluate COVID-19 infection in relation to 156 confounders. There was no difference in the odd of being infected with SARS-CoV-2 between the two groups, 157 indicating that COVID-19 infection was not an independent predictor of abortion (1.282, CI 0.53-3.08). In the case group, 5/11 (45.4%), 3/11 (27.2%), and 1/11 (9%) were positive for SARS-CoV-2 IgG, SARS-CoV-2 IgM, 159 or both SARS-CoV-2 IgG and IgM, respectively; RT-PCR of the nasopharingeal swab resulted positive in 2/11 (18%) 160 (Table 2 ). In the control group, 7/12 (58.3%), 3/12 (25%), and 2/12 (16.6%) were positive for SARS-CoV-2 IgG, 161 SARS-CoV-2 IgM, or both SARS-CoV-2 IgG and IgM, respectively; RT-PCR of the nasopharingeal swab resulted 162 positive in 5/12 (41.7%) ( Table 3) . No difference in positivity for IgG neutralizing antibodies was found between the 163 case (6/11, 54.5%) and the control group (5/12, 41.7%) (p=0.53) ( Table 1 ). There was no statistically significant 164 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 20, 2020. Hospital admission due to COVID-19-related symptoms was recorded. No difference in the incidence of symptoms was 169 noted between the case (4/11, 36.4%) and the control group (8/12, 66.6%) (p=0.14). . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 20, 2020. Despite these reassuring data, pregnancies in women with COVID-19 can still have an unfavorable obstetric outcome: 221 inflammatory involvement of the placenta 27 can be associated with preterm delivery. 28 Moreover, physiologic maternal 222 adaptations to pregnancy predispose pregnant women to a more severe course of pneumonia, with subsequent higher 223 maternal and fetal morbidity and mortality. 29 In this cohort, however, few patients were symptomatic and not more 224 numerous in the case group. Severe disease was never observed. The lower incidence of severe manifestations during 225 the first trimester could be explained by the minimal alteration in respiratory dynamics during this phase of pregnancy. In conclusion, our study provides reassuring findings for women who intend to become pregnant during the SARS- . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 20, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 20, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 20, 2020. . https://doi.org/10.1101/2020.06.19.20135749 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 20, 2020. . https://doi.org/10.1101/2020.06.19.20135749 doi: medRxiv preprint Coronaviruses: an overview of their replication and pathogenesis A Novel Coronavirus from Patients with Pneumonia in China Coronavirus disease 2019 in pregnant women: a report based on 116 cases Clinical analysis of ten pregnant women with COVID-19 in Wuhan, China: A 254 retrospective study Vaginal delivery in SARS-CoV-2-infected pregnant women in Northern Italy: 256 a retrospective analysis Analysis of vaginal delivery outcomes among pregnant women in 258 China during the COVID-19 pandemic COVID-19 infection among asymptomatic and symptomatic 261 pregnant women: Two weeks of confirmed presentations to an affiliated pair of New York City Hospitals Universal Screening for SARS-CoV-2 in Women Admitted for 264 Outcome of Coronavirus spectrum infections (SARS, MERS, COVID 1 -266 19) during pregnancy: a systematic review and meta-analysis Is termination of early pregnancy indicated in women with Validation of a chemiluminescent assay for 272 specific SARS-CoV-2 antibody Clinical course and risk factors for mortality of adult inpatients with COVID-19 in 275 China: a retrospective cohort study Screening all pregnant women admitted to labor and delivery for the 277 virus responsible for coronavirus disease 2019 COVID-19 Antibody Testing in Pregnancy Antibody responses to SARS-CoV-2 in patients with COVID-19 Pre-labor anorectal swab for SARS-CoV-2 in COVID-19 patients: is it time to 286 think about it? Possible Vertical Transmission of SARS-CoV-2 From an Infected Mother to Her 289 Newborn COVID-19 and ART: the view of the Italian Society of Fertility and 291 Sterility and Reproductive Medicine Global interim guidance on coronavirus disease 2019 (COVID-19) during 294 pregnancy and puerperium from FIGO and allied partners: Information for healthcare professionals How to reduce the potential risk of vertical transmission 297 of SARS-CoV-2 during vaginal delivery? Coronavirus Disease 2019 (COVID-19) and 300 Pregnancy: What obstetricians need to know Pregnancy and perinatal outcomes of women with severe acute respiratory 303 syndrome Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection 305 during pregnancy: Report of two cases & review of the literature Second-Trimester Miscarriage in a Pregnant Woman With SARS-CoV-2 Infection Visualization of SARS-CoV-2 virus invading the human placenta 309 using electron microscopy Placental Pathology in COVID-19 Analysis of Maternal Coronavirus Infections and Neonates Born to 313 Mothers with 2019-nCoV; a Systematic Review ISUOG Interim Guidance on 2019 novel coronavirus infection during pregnancy 315 and puerperium: information for healthcare professionals Coronavirus disease 2019 (COVID-19) and pregnancy: a systematic review